Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC

Thursday, September 18, 2008 General News J E 4
BOSTON, Sept. 18 Scimitar Equity, LLC issues a Q4/08review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled,"Defining Outcome Scenarios, Probabilities Appear Focused to the Upside andFuture Appreciation." This review is available at our

Neurobiological Technologies, Inc. (NTII) is a biotechnology companyengaged in the business of acquiring and developing central nervous systemrelated drug candidates. NTII is a specialty biopharmaceutical company withexpertise in identifying and acquiring promising drug candidates and indesigning and managing late-stage clinical trials for central nervous systemconditions. Neurobiological Technologies, Inc. is currently developingViprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3trials for the treatment of acute ischemic stroke. For further information,please visit NTII's website at

Scimitar Equity, LLC provides sponsored equity research of emerginghealthcare companies for the investing communities. We certify that all theviews expressed in this review, accurately reflect our personal views aboutNTII (NASDAQ) and its or their securities. Investors are advised that thisanalysis and review is issued solely for informational purposes and is not tobe construed as an offer to sell or the solicitation of an offer to buy.Scimitar was paid for preparing this review. This analysis and review isbased on sources that we believe to be reliable but is not guaranteed by us asbeing accurate and does not purport to be a complete statement or summary ofthe available data. Any opinions expressed are statements of our own judgmentas of the date of publication and are subject to change without notice.Please read all our important disclosures.CONTACT: Scimitar Equity, LLC Henry W. McCusker Director of Research phone: (617) 559.1080 e-mail:

SOURCE Scimitar Equity, LLC


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
WebMD and Commission on Presidential Debates to Pa...
The Kaiser Family Foundation and Univision Launch ...